A Case of Lung Adenocarcinoma Harboring a Rare LOC285000-ALK-NCK2 Gene Fusion Identified by Next-Generation Sequencing With Long-Term Response to Crizotinib

Most patients with NSCLC, initially sensitive, will develop resistance after a period of time after the application of ALK inhibitors. We present here a rare LOC285000-ALK-NCK2 gene fusion with response to crizotinib treatment; the patient achieved a progression-free survival of 23 months.

Detalles Bibliográficos
Autores principales: Zhang, Min, Zhou, Huan, Liu, Dan, Yu, Ruoying, Chen, Jun
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Elsevier 2020
Materias:
Case Report
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8474267/
https://www.ncbi.nlm.nih.gov/pubmed/34589983
http://dx.doi.org/10.1016/j.jtocrr.2020.100106

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8474267/
https://www.ncbi.nlm.nih.gov/pubmed/34589983
http://dx.doi.org/10.1016/j.jtocrr.2020.100106

Ejemplares similares